Navigation Links
Tiny capsules deliver
Date:1/12/2009

A tiny particle syringe composed of polymer layers and nanoparticles may provide drug delivery that targets diseased cells without harming the rest of the body, according to a team of chemical engineers. This delivery system could be robust and flexible enough to deliver a variety of substances.

"People probably fear the effects of some treatments more than they fear the disease they treat," says Huda A. Jerri, graduate student, chemical engineering. "The drugs are poison. Treatment is a matter of dosage so that it kills the cancer and not the patient. Targeted treatment becomes very important."

Newer approaches to drug delivery include particles that find specific cells, latch on and release their drugs. Another approach allows the cells to engulf the particles, taking them into the cell and releasing the drug. However, the requirements for these delivery systems are complicated and challenging to implement.

The Penn State researchers' approach produces a more universal delivery system, a tiny spherical container averaging less than 5 microns or the diameter of the smallest pollen grains.

The spheres are formed around solid microparticles that are either the drug to be delivered or a substance that can be removed later leaving a hollow sphere for liquid drugs. They reported their results online in Soft Matter.

Alternating positive and negative layers of material form the microcapsules. The capsules are created while attached to a flat surface so the section of the sphere touching the surface is not coated, leaving about 5 percent of the surface as an escape area for the drugs. The microcapsule, excluding the exit hole, is then covered in a slippery, non-stick barrier coating.

"These are not the first microcapsules for drug delivery developed, but a previous attempt had surfaces that stuck together and clumped," says Velegol. "We also designed the tiny hole in the sphere for controlled delivery and that is a new development."

Targeted drug delivery systems release their drug from the moment they enter the body. The microsyringes, however, while releasing material continuously, do so only from the tiny hole in their surface and not from the other 95 percent of the sphere's surface. This will concentrate the drug at the target and reduce the amount of toxins circulating in the body.

"These particles are delivery vessels to which you can add whatever you want when you need it," says Jerri. "Drugs can be either solid -- incorporated when the capsules are made -- or liquid -- filled later. Chemicals that target the diseased cells can be attached in a variety of ways."

To serve as viable, flexible drug delivery systems, these microcapsules should be off the shelf and not completely tailor made for each application. The researchers tested the robustness of the microsyringes by dehydrating and then reconstituting them. Their ability to withstand long periods dried out and then successfully rehydrate is important both for shelf life and because that is the way that liquid medications will be inserted in the microcapsules as needed.

To ensure that the spheres refill, the researchers used a solution containing fluorescent dyes. The filling and emptying of the microcapsules are controlled by the acidity of the liquid in which the tiny beads float. Successful rehydration and filling suggest that these microsyringes could be manufactured and stored until needed. They could then be filled with the appropriate drug and have the proper targeting agent attached to treat specific diseases and patients.

"The masking process used to manufacture these microcapsules is relatively inexpensive, current technology and is scalable," says Velegol. "This means they could be mass produced."


'/>"/>

Contact: A'ndrea Elyse Messer
aem1@psu.edu
814-865-9481
Penn State
Source:Eurekalert  

Related medicine news :

1. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
2. Barr Confirms Patent Challenge of Amrix(R) Extended-Release Capsules, 15mg & 30mg
3. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
4. Watson Launches Omeprazole Delayed-Release Capsules, 40MG
5. Watson Launches Generic MARINOL(R) Capsules
6. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
7. Lupin Launches Ramipril Capsules
8. Mylan Announces Final FDA Approval for Zaleplon Capsules
9. Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
10. Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
11. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tiny capsules deliver
(Date:2/5/2016)... Lake City, UT (PRWEB) , ... February 05, 2016 , ... ... Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist ... Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... the election of Patrick McDermott as Chairman of the National Board of Directors. Mr. ... as Chairman of the Board,” stated Leslie A. Chambers , APDA President and ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
Breaking Medicine Technology: